Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]
Awaiting development
Reference number: GID-TA12518
Expected publication date: TBC
This is the deferred appraisal of D5. Scoping documents can be found on the record for D5.